35. EVALUATING THE RESULT LINE 1 OF TREATMENT NON SMALL CELL LUNG CANCER PATIENTS STAGE IV HABOR EGFR MUTATION BY OSIMERTINIB AT NATIONAL LUNG HOSPITAL FROM 2019 TO 2022. YHCĐ [Internet]. 2024 May 15 [cited 2026 Sept. 8];65(CĐ 3 - Bệnh viện Phổi Trung ương). Available from: https://tapchiyhcd.vn/index.php/yhcd/article/view/1132